ArticleNature communications2022
Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
163 citing papers in PubMed, 2 syntheses or guidelines pooled it, 271 citations in OpenAlex.
- Evolutionary dynamics and research hotspots of phage applications againstFrontiers in microbiology · 2026Pooled it
- The impact of different antibiotic injection regimens on patients with severe infections: A meta-analysis.International wound journal · 2024Pooled it
- Klebsiella genus as driver of human disease: from infections to non-communicable disorders.Nature reviews. Microbiology · 2026Review
- Bacteriophages in the treatment of cutaneous infections and skin disorders: therapeutic advances and future directions.Clinical microbiology reviews · 2026Review
- Genomic characterization and therapeutic potential of five broad-spectrum lytic bacteriophages against multidrug-resistant avian pathogenicMicrobiology spectrum · 2026Article
- Addressing antimicrobial resistance: Current challenges, emerging strategies, and an AI-powered, community-driven approach.PNAS nexus · 2026Review
- Harnessing lytic phages for biofilm control in carbapenem-resistantMicrobiology spectrum · 2026Article
- [Bacteriophage Therapy in Orthopaedics and Trauma].Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca · 2026Review
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The effects of bacteriophage cocktail treatment on healthy gut microbiota: anMicrobial genomics · 2026Article
- Engineered phages evade the complete defense repertoire of highly phage-resistant MRSA clinical isolates.bioRxiv : the preprint server for biology · 2026Article
- A novel phage preparation capable of simultaneously inhibiting both K1 and K2 serotypes ofApplied and environmental microbiology · 2026Article
- Engineered Bacteriophages: A Next-Generation Platform for Precision Antimicrobials and Therapeutics.Viruses · 2026Review
- Genome characterization and receptor-binding protein identification of Klebsiella phage vB_VIPKPNMC05, a member of a novel viral family Pituviridae.Archives of virology · 2026Article
- Review
- Combined bacteriophage and antibiotic therapy for refractory peritoneal dialysis-related peritonitis caused by Klebsiella pneumoniae.Nature communications · 2026Article
- 3D Printing of Bacteriophage-Loaded Hydrogels: Development of a Local and Long-Lasting Delivery System.Advanced healthcare materials · 2026Article
- Novel Autographivirales phages Kiwi, Nika and Pie targeting Klebsiella pneumoniae K14: Isolation, characterisation, genome analysis and study of the bacterial polysaccharide degradation.Archives of virology · 2026Article
- Steering the course: targeting and exploiting surface receptors in phage therapy.Journal of bacteriology · 2026Review
- Bacteriophage Therapy AgainstMicroorganisms · 2026Review
103 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 30-year-old bombing victim with a fracture-related pandrug-resistant Klebsiella pneumoniae infection after long-term (>700 days) antibiotic therapy is treated with a pre-adapted bacteriophage along with meropenem and colistin, followed by ceftazidime/avibactam. This salvage therapy results in objective clinical, microbiological and radiological improvement of the patient's wounds and overall condition. In support, the bacteriophage and antibiotic combination is highly effective against the patient's K. pneumoniae strain in vitro, in 7-day mature biofilms and in suspensions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.